DE69836199D1 - Anti-invasive and anti-angiogene urokinase fragmente und deren verwendung - Google Patents

Anti-invasive and anti-angiogene urokinase fragmente und deren verwendung

Info

Publication number
DE69836199D1
DE69836199D1 DE69836199T DE69836199T DE69836199D1 DE 69836199 D1 DE69836199 D1 DE 69836199D1 DE 69836199 T DE69836199 T DE 69836199T DE 69836199 T DE69836199 T DE 69836199T DE 69836199 D1 DE69836199 D1 DE 69836199D1
Authority
DE
Germany
Prior art keywords
angiogenesis
pro
glu
ser
variant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69836199T
Other languages
English (en)
Other versions
DE69836199T2 (de
Inventor
R Jones
P Mazar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ANGSTROM PHARMACEUTICALS, INC., SOLANA BEACH, , US
Original Assignee
Angstrom Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Angstrom Pharmaceuticals Inc filed Critical Angstrom Pharmaceuticals Inc
Publication of DE69836199D1 publication Critical patent/DE69836199D1/de
Application granted granted Critical
Publication of DE69836199T2 publication Critical patent/DE69836199T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6456—Plasminogen activators
    • C12N9/6462—Plasminogen activators u-Plasminogen activator (3.4.21.73), i.e. urokinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21073—Serine endopeptidases (3.4.21) u-Plasminogen activator (3.4.21.73), i.e. urokinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Materials For Medical Uses (AREA)
DE69836199T 1997-07-25 1998-07-24 Anti-invasive and anti-angiogene urokinase fragmente und deren verwendung Expired - Lifetime DE69836199T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US900327 1997-07-25
US08/900,327 US5994309A (en) 1997-07-25 1997-07-25 Anti-invasive and anti-angiogenic compositions and methods
PCT/US1998/015437 WO1999005263A1 (en) 1997-07-25 1998-07-24 Anti-invasive and anti-angiogenic urokinase fragments and their use

Publications (2)

Publication Number Publication Date
DE69836199D1 true DE69836199D1 (de) 2006-11-30
DE69836199T2 DE69836199T2 (de) 2007-09-13

Family

ID=25412335

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69836199T Expired - Lifetime DE69836199T2 (de) 1997-07-25 1998-07-24 Anti-invasive and anti-angiogene urokinase fragmente und deren verwendung

Country Status (11)

Country Link
US (5) US5994309A (de)
EP (1) EP0950096B1 (de)
AT (1) ATE342967T1 (de)
AU (1) AU752205B2 (de)
CA (1) CA2269772A1 (de)
CY (1) CY1107051T1 (de)
DE (1) DE69836199T2 (de)
DK (1) DK0950096T3 (de)
ES (1) ES2275309T3 (de)
PT (1) PT950096E (de)
WO (1) WO1999005263A1 (de)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030144570A1 (en) * 1999-11-12 2003-07-31 Angiotech Pharmaceuticals, Inc. Compositions and methods for treating disease utilizing a combination of radioactive therapy and cell-cycle inhibitors
US7361643B2 (en) 2000-02-09 2008-04-22 University Of Puerto Rico Methods for inhibiting angiogenesis
WO2001066144A2 (en) * 2000-03-08 2001-09-13 Rhode Island Hospital, A Lifespan Partner Antineoplastic combination comprising an inhibitor of angiogenesis and an inhibitor of dna topoisomerase i enzyme activity
AU2001253479A1 (en) 2000-04-13 2001-10-30 Sts Biopolymers, Inc. Targeted therapeutic agent release devices and methods of making and using the same
WO2002038799A2 (en) * 2000-11-07 2002-05-16 University Of Victoria Innovation And Development Corporation Detection of proteases and screening for protease inhibitors
DE60207043T2 (de) 2001-02-05 2006-07-13 Innoventus Project Ab Histidin-reiches glykoprotein (hrgp) zur inhibierung der angiogenese
US6589997B2 (en) * 2001-06-29 2003-07-08 North Shore-Long Island Jewish Health System Small-molecule modulators of hepatocyte growth factor/scatter factor activities
EP1494695A4 (de) * 2002-04-15 2006-01-25 American Nat Red Cross Plasmaprotein-bindungsliganden
PL377701A1 (pl) * 2002-11-25 2006-02-06 Attenuon, Llc Peptydy, które namierzają komórki nowotworowe i śródbłonkowe, kompozycje i ich zastosowania
IL156566A0 (en) * 2003-06-19 2004-01-04 Hadasit Med Res Service Urokinase plasminogen activator derived octapeptide in the treatment of multiple sclerosis
WO2005002526A2 (en) * 2003-07-01 2005-01-13 President And Fellows Of Harvard College Method and compositions for treatment of viral infections
WO2005027895A2 (en) 2003-09-15 2005-03-31 Ordway Research Institute Thyroid hormone analogs and methods of use in angiogenesis
US9198887B2 (en) 2003-09-15 2015-12-01 Nanopharmaceuticals Llc Thyroid hormone analogs and methods of use
US8668926B1 (en) 2003-09-15 2014-03-11 Shaker A. Mousa Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations thereof
US8071134B2 (en) * 2003-09-15 2011-12-06 Ordway Research Institute, Inc. Thyroid hormone analogs and methods of use
US20050101582A1 (en) 2003-11-12 2005-05-12 Allergan, Inc. Compositions and methods for treating a posterior segment of an eye
US8722097B2 (en) 2004-04-30 2014-05-13 Allergan, Inc. Oil-in-water method for making polymeric implants containing a hypotensive lipid
US9498457B2 (en) 2004-04-30 2016-11-22 Allergan, Inc. Hypotensive prostamide-containing biodegradable intraocular implants and related implants
US7993634B2 (en) 2004-04-30 2011-08-09 Allergan, Inc. Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods
US7799336B2 (en) 2004-04-30 2010-09-21 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
TWI366459B (en) * 2004-09-28 2012-06-21 Ind Tech Res Inst Novel hydrophilic analogs of 4,8-dihydrobenzodithiophene-4,8-diones as anticancer agents
US9220788B2 (en) * 2009-06-17 2015-12-29 Nanopharmaceuticals Llc Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations and uses thereof
US9498536B2 (en) 2005-09-15 2016-11-22 Nanopharmaceuticals Llc Method and composition of thyroid hormone analogues and nanoformulations thereof for treating anti-inflammatory disorders
US10130686B2 (en) 2005-09-15 2018-11-20 Nanopharmaceuticals Llc Method and composition of thyroid hormone analogues and nanoformulations thereof for treating inflammatory disorders
US20100209382A1 (en) 2005-09-16 2010-08-19 Ordway Research Institute, Inc. Polyphenol Conjugates as RGD-Binding Compounds and Methods of Use
US20070134739A1 (en) * 2005-12-12 2007-06-14 Gyros Patent Ab Microfluidic assays and microfluidic devices
US8524663B2 (en) 2006-03-03 2013-09-03 New York University Method for site-specific polyvalent display on polymers
EP2037270A3 (de) * 2006-03-31 2009-03-25 F. Hoffmann-La Roche Ag Tumormodell unter Verwendung von grünem Fluoreszenzprotein
US8039010B2 (en) 2006-11-03 2011-10-18 Allergan, Inc. Sustained release intraocular drug delivery systems comprising a water soluble therapeutic agent and a release modifier
US8969415B2 (en) 2006-12-01 2015-03-03 Allergan, Inc. Intraocular drug delivery systems
WO2008140507A2 (en) * 2006-12-22 2008-11-20 Clf Medical Technology Acceleration Program, Inc. Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations and uses thereof
US8481273B2 (en) * 2008-06-20 2013-07-09 University Of Delaware Perlecan fragments as biomarkers of bone stromal lysis
US20100159021A1 (en) * 2008-12-23 2010-06-24 Paul Davis Small Molecule Ligands of the Integrin RGD Recognition Site and Methods of Use
US8313914B2 (en) * 2009-03-06 2012-11-20 Angstrom Pharmaceuticals, Inc. Compositions and methods for modulation of cell migration
WO2010120506A1 (en) * 2009-03-31 2010-10-21 Ordway Research Institute, Inc. Combination treatment of cancer with cetuximab and tetrac
EP2525776B1 (de) 2010-01-22 2015-10-28 Allergan, Inc. Intrakamerale implantate mit retard-therapeutika
AU2011223563A1 (en) * 2010-03-05 2012-11-01 Angstrom Pharmaceuticals, Inc. Modulation of intracellular signaling
US8802240B2 (en) 2011-01-06 2014-08-12 Nanopharmaceuticals Llc Uses of formulations of thyroid hormone analogs and nanoparticulate forms thereof to increase chemosensitivity and radiosensitivity in tumor or cancer cells
US10060934B2 (en) 2013-11-18 2018-08-28 Nanopharmaceuticals Llc Methods for screening patients for resistance to angioinhibition, treatment and prophylaxis thereof
US20190381127A1 (en) 2016-02-02 2019-12-19 Splash Pharmaceuticals, Inc. Combination therapy with a6, chemotherapeutic agents, radiation therapy, or a combination thereof for the treatment of cancer
US10201616B2 (en) 2016-06-07 2019-02-12 Nanopharmaceuticals, Llc Non-cleavable polymer conjugated with αVβ3 integrin thyroid antagonists
CN107722115A (zh) * 2017-11-29 2018-02-23 吉林大学 一种新型重组蜂毒多肽及其制备方法和应用
US10328043B1 (en) 2018-04-11 2019-06-25 Nanopharmaceuticals, Llc. Composition and method for dual targeting in treatment of neuroendocrine tumors
US11351137B2 (en) 2018-04-11 2022-06-07 Nanopharmaceuticals Llc Composition and method for dual targeting in treatment of neuroendocrine tumors
CN109180822B (zh) * 2018-11-14 2021-08-10 上海交通大学 一种猪链球菌b细胞优势表位串联疫苗及其制备方法
CN111603567A (zh) 2019-02-22 2020-09-01 博瑞生物医药（苏州）股份有限公司 Cd44靶向多臂偶联物
US10961204B1 (en) 2020-04-29 2021-03-30 Nanopharmaceuticals Llc Composition of scalable thyrointegrin antagonists with improved blood brain barrier penetration and retention into brain tumors
US11723888B2 (en) 2021-12-09 2023-08-15 Nanopharmaceuticals Llc Polymer conjugated thyrointegrin antagonists

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5422090A (en) * 1984-08-13 1995-06-06 Biotechnology Australia, Pty., Ltd. Human PAI-2
IL81879A (en) 1986-03-13 1994-07-31 Biotech Australia Pty Ltd Purification of minactivin for homogeneity, production of minactivin as recombinant techniques, and uses of homogeneous or recombinant minactivin
US5073626A (en) * 1988-11-09 1991-12-17 Monsanto Company Affinity purification of plasminogen activator inhibitor I using a modified urokinase
DK0467932T3 (da) 1989-04-07 2001-02-12 Cancerforskningsfonden Af 1989 Plasminogen-aktivator-receptor af urokinasetypen
DK182289D0 (da) * 1989-04-14 1989-04-14 Francesco Blasi Modifikation af proteiner
AU6275690A (en) 1989-08-09 1991-03-11 Delta Biotechnology Limited Polypeptide production in fungi
GB8919803D0 (en) * 1989-09-01 1989-10-18 Ciba Geigy Pharmaceutical compositions
WO1991009124A1 (en) * 1989-12-20 1991-06-27 Biotech Australia Pty. Limited Variants of pai-2
GB2246779B (en) 1990-08-03 1994-08-17 Delta Biotechnology Ltd Tumour-associated protease inhibitors targeted to tumour cells
US5470970A (en) * 1991-02-28 1995-11-28 Dana-Farber Cancer Institute, Inc. Maspin, a serpin with tumor suppresing activity
US5382514A (en) * 1992-03-31 1995-01-17 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services In vivo angiogenesis assay
DE69328092T2 (de) 1992-05-28 2000-07-20 Univ Toledo Bereitstellung einer für krebszellen cytotoxischen verbindung unter verwendung des weges von plasminogenaktivatormaterial
EP0673384A4 (de) * 1992-12-10 1996-10-09 Univ Minnesota Polypeptide nützlich in der behandlung von entzündlichen erkrankungen.
EP0745092B1 (de) * 1993-05-28 1999-07-21 Chiron Corporation Peptidinhibitoren der urokinaserezeptor-aktivität
DE69432608T2 (de) 1993-06-01 2004-02-26 Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville Expression von inhibitoren vom plasminogenaktivator vom urokinasetyp
DK85193D0 (da) 1993-07-16 1993-07-16 Cancerforskningsfondet Af 1989 Suppression of inhibitors
IT1271684B (it) 1994-07-22 1997-06-04 Consiglio Nazionale Ricerche Oligonucleotidi antisenso complementari all'rna messaggero del recettore umano della urochinasi
WO1997005257A1 (en) * 1995-07-31 1997-02-13 Chiron Corporation Peptide analog inhibitors of urokinase receptor activity
US6509445B1 (en) * 1996-01-08 2003-01-21 Nissin Food Products Co., Ltd. Cancerous metastasis inhibitor

Also Published As

Publication number Publication date
US20090143303A1 (en) 2009-06-04
AU752205B2 (en) 2002-09-12
CY1107051T1 (el) 2012-10-24
ATE342967T1 (de) 2006-11-15
US20030027768A1 (en) 2003-02-06
US5994309A (en) 1999-11-30
US6696416B1 (en) 2004-02-24
US7807621B2 (en) 2010-10-05
DE69836199T2 (de) 2007-09-13
PT950096E (pt) 2007-02-28
US8110543B2 (en) 2012-02-07
EP0950096B1 (de) 2006-10-18
CA2269772A1 (en) 1999-02-04
WO1999005263A1 (en) 1999-02-04
EP0950096A1 (de) 1999-10-20
ES2275309T3 (es) 2007-06-01
US20110065640A1 (en) 2011-03-17
AU8590098A (en) 1999-02-16
DK0950096T3 (da) 2007-02-19

Similar Documents

Publication Publication Date Title
DE69836199D1 (de) Anti-invasive and anti-angiogene urokinase fragmente und deren verwendung
MY128654A (en) Liquid pharmaceutical composition containing an erythropoietin derivative
KR970707141A (ko) 종양 괴사 인자-감마(Tumor necrosis factor-gamma)
JP2008501310A (ja) 胃腸障害の治療のための方法および組成物
WO1997030085B1 (en) Troponin subunits and fragments useful as angiogenesis inhibitors
MA26458A1 (fr) Nouveaux derives cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent.
RU98123834A (ru) СПОСОБЫ И КОМПОЗИЦИИ, ИСПОЛЬЗУЕМЫЕ ДЛЯ ИНГИБИРОВАНИЯ αvβ5ОПОСРЕДОВАННОГО АНГИОГЕНЕЗА
TR200100377T2 (tr) Aß Protein üretimi inhibitörleri olarak sukinoilamino laktamlar.
JP5372096B2 (ja) 新規な抗腫瘍化合物
PT2132221E (pt) Peptidomiméticos fixados num molde
CN109248310B (zh) 利用θ-防御素的炎性蛋白酶的阻断
KR920004418A (ko) 브래디키닌 길항제
RU95111308A (ru) Производные 2-амино-4-фенил-4-оксомасляной кислоты, способы получения, фармацевтическая композиция
DE60008399D1 (de) Carbonsäuren und acylsulfonamide, solche verbindungen enthaltende zubereitungen und behandlungsmethoden
KR20000005210A (ko) 고리형 부착 억제제_
MXPA05005545A (es) Peptidos que se dirigen a celulas tomurales y endoteliales, composiciones y usos de los mismos.
EP1194531B1 (de) Zyklische peptidomimetische urokinaserezeptorantagonisten
WO1998046632A2 (de) Inhibitoren für den urokinaserezeptor
SE9700244D0 (sv) Novel antibacterial protein
Cai et al. Recent developments in targeting bromodomain and extra terminal domain proteins for cancer therapeutics
DE19534016A1 (de) Biotinderivate
EP0670165B1 (de) Verwendung der Seminalribonuklease als antimetastatische Verbindung
GR3031254T3 (en) Novel derivatives of peptides therapeutically active in the cascade sequence for blood coagulation, process for their preparation and pharmaceutical compositions containing same
US20210238229A1 (en) Peptide for disease treatment
AR030293A1 (es) Una composicion de vacuna que comprende una proteina receptora de fc; un metodo para prepararla; uso de dicha proteina y de un polinucleotido que codifica para dicha proteina y un metodo para tratar o prevenir una infeccion bacteriana

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: ANGSTROM PHARMACEUTICALS, INC., SOLANA BEACH, , US

8364 No opposition during term of opposition